
Emerging Risk | Semaglutides: weighing up the risks
Update: 2025-04-22
Share
Description
The first episode of our 2025 podcast series covers Semaglutides, a diabetes control drug that works by activating glucagon-like peptide-1 (GLP-1) receptors to suppress appetite.
Comments
In Channel